Migraine Preventive Treatment Meets Primary Endpoint in Trial

Article

Allergan announced positive topline results from CGP-MD-01, a phase 2b/3 clinical trial of atogepant.

Allergan announced positive topline results from CGP-MD-01, a phase 2b/3 clinical trial of atogepant.

All active treatment arms met the primary endpoint of a statistically significant reduction from baseline in monthly migraine/probable migraine (MPM) headache days in patients treated with atogepant compared with placebo.

“What these data, coupled with the data from ubrogepant, mean is that for the first time we have a mechanism of action that demonstrated efficacy and safety for both the treatment and prevention of migraine,” David Nicholson, PhD, Chief Research and Development Officer, Allergan told

MD Magazine

.

The migraine prophylaxis was tested as a daily or twice-daily treatment for patients with episodic migraine. Other migraine preventatives currently being studied, such as galcanezumab and fremanezumab, are injected on a monthly or quarterly basis.

Click to continue reading on MD Magazine.

Even more resources pertaining to headaches and migraines can be found on Specialty Pharmacy Times' new sister site, NeurologyLive.

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.